JWH-161: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:JWH-161}} | |||
== | == Overview == | ||
'''JWH-161''' is a synthetic [[cannabinoid]] that acts as a potent agonist at the [[cannabinoid receptor]]s. It is part of the [[naphthoylindole]] family, which is known for its psychoactive properties. JWH-161 was developed in the 1990s by [[John W. Huffman]] and his team at [[Clemson University]] as part of their research into the effects of cannabinoids on the [[endocannabinoid system]]. | |||
JWH-161 | == Chemical Structure == | ||
[[File:JWH-161.svg|thumb|right|Chemical structure of JWH-161]] | |||
JWH-161 has a chemical structure that includes a naphthoyl group attached to an indole core. This structure is similar to other synthetic cannabinoids, which often mimic the structure of [[tetrahydrocannabinol]] (THC), the primary psychoactive component of [[cannabis]]. | |||
== | == Pharmacology == | ||
JWH-161 acts as a full agonist at both the [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]] cannabinoid receptors. These receptors are part of the [[G protein-coupled receptor]] family and are involved in a variety of physiological processes, including [[pain modulation]], [[appetite regulation]], and [[immune response]]. | |||
JWH-161 | === CB1 Receptor === | ||
The CB1 receptor is primarily found in the [[central nervous system]], where it modulates neurotransmitter release. Activation of CB1 by JWH-161 can lead to effects such as [[analgesia]], [[euphoria]], and [[cognitive impairment]]. | |||
== | === CB2 Receptor === | ||
The CB2 receptor is mainly expressed in the [[immune system]] and peripheral tissues. JWH-161's action on CB2 can influence [[inflammation]] and [[immune cell]] migration. | |||
== Legal Status == | == Legal Status == | ||
The legal status of JWH-161 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. The [[United States]], for example, has placed many synthetic cannabinoids, including JWH-161, under Schedule I of the [[Controlled Substances Act]]. | |||
== Potential Risks and Side Effects == | |||
The use of JWH-161, like other synthetic cannabinoids, can pose significant health risks. These may include [[tachycardia]], [[hypertension]], [[anxiety]], and [[psychosis]]. Long-term use can lead to [[addiction]] and [[withdrawal symptoms]]. | |||
== | |||
The use of JWH-161 can | |||
== | == Research and Applications == | ||
Research into JWH-161 and similar compounds continues, with a focus on understanding their effects on the endocannabinoid system and potential therapeutic applications. However, due to their psychoactive properties and legal restrictions, research is often limited. | |||
== Related Pages == | |||
* [[Synthetic cannabinoids]] | * [[Synthetic cannabinoids]] | ||
* [[Cannabinoid receptor]] | * [[Cannabinoid receptor]] | ||
* [[John W. Huffman]] | * [[John W. Huffman]] | ||
* [[ | * [[Naphthoylindole]] | ||
[[Category:Synthetic cannabinoids]] | [[Category:Synthetic cannabinoids]] | ||
[[Category: | [[Category:Research chemicals]] | ||
Latest revision as of 03:38, 13 February 2025
Overview[edit]
JWH-161 is a synthetic cannabinoid that acts as a potent agonist at the cannabinoid receptors. It is part of the naphthoylindole family, which is known for its psychoactive properties. JWH-161 was developed in the 1990s by John W. Huffman and his team at Clemson University as part of their research into the effects of cannabinoids on the endocannabinoid system.
Chemical Structure[edit]
JWH-161 has a chemical structure that includes a naphthoyl group attached to an indole core. This structure is similar to other synthetic cannabinoids, which often mimic the structure of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.
Pharmacology[edit]
JWH-161 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors. These receptors are part of the G protein-coupled receptor family and are involved in a variety of physiological processes, including pain modulation, appetite regulation, and immune response.
CB1 Receptor[edit]
The CB1 receptor is primarily found in the central nervous system, where it modulates neurotransmitter release. Activation of CB1 by JWH-161 can lead to effects such as analgesia, euphoria, and cognitive impairment.
CB2 Receptor[edit]
The CB2 receptor is mainly expressed in the immune system and peripheral tissues. JWH-161's action on CB2 can influence inflammation and immune cell migration.
Legal Status[edit]
The legal status of JWH-161 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. The United States, for example, has placed many synthetic cannabinoids, including JWH-161, under Schedule I of the Controlled Substances Act.
Potential Risks and Side Effects[edit]
The use of JWH-161, like other synthetic cannabinoids, can pose significant health risks. These may include tachycardia, hypertension, anxiety, and psychosis. Long-term use can lead to addiction and withdrawal symptoms.
Research and Applications[edit]
Research into JWH-161 and similar compounds continues, with a focus on understanding their effects on the endocannabinoid system and potential therapeutic applications. However, due to their psychoactive properties and legal restrictions, research is often limited.
